BPR-30221616 / Chengdu Brilliant Pharma - LARVOL DELTA

A Safety and Tolerability Study of BPR-30221616 Injection in Healthy Subjects (clinicaltrials.gov) - P1 | N=48 | Recruiting | Sponsor: Chengdu Brilliant Pharmaceutical Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open

11 Class 1 innovative drugs were approved for clinical trials in China for the first time!… [Google translation] (Sina Corp) - "Mengke Pharmaceuticals' Class 1 new drug MRX-5 tablets have been approved for clinical trials. The product is intended to treat infections caused by nontuberculous mycobacteria (NTM) that are sensitive to this product...Beite Pharmaceuticals' Class 1 new drug BPR-30221616 injection has been approved for clinical trials and is intended to be developed to treat transthyretin amyloid cardiomyopathy...The Class 1 new drug CM559 injection applied by Conoya has been approved for clinical trials and is intended to be developed to treat Alzheimer's disease...The Class 1 new drug ART101 injection filed by Ontop Biopharmaceuticals has been approved for clinical trials and is intended to be developed for the treatment of hypertension....Sanofi 's Class 1 new drug SAR442970 injection has been approved for clinical use and is intended to treat primary focal segmental glomerulosclerosis (FSGS) or primary minimal change nephropathy (MCD) in adults and adolescents aged 16 and above."

New trial • Alzheimer's Disease • Cardiomyopathy • Focal Segmental Glomerulosclerosis • Hypertension • Nontuberculous Mycobacterial Disease

A Safety and Tolerability Study of BPR-30221616 Injection in Healthy Subjects (clinicaltrials.gov) - P1 | N=48 | Not yet recruiting | Sponsor: Chengdu Brilliant Pharmaceutical Co., Ltd.

New P1 trial